Indivior PLC (LON:INDV) has been assigned a consensus rating of “Buy” from the seven research firms that are currently covering the stock. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is GBX 369.29 ($4.61).

INDV has been the topic of several research analyst reports. Numis Securities Ltd reiterated a “buy” rating and set a GBX 340 ($4.25) price target on shares of Indivior PLC in a research note on Friday, July 29th. Stifel Nicolaus reiterated a “buy” rating and set a GBX 350 ($4.37) price target on shares of Indivior PLC in a research note on Friday, July 29th. Jefferies Group boosted their price target on Indivior PLC from GBX 320 ($4.00) to GBX 330 ($4.12) and gave the company a “buy” rating in a research note on Monday, August 1st. Morgan Stanley boosted their price target on Indivior PLC from GBX 280 ($3.50) to GBX 330 ($4.12) and gave the company an “overweight” rating in a research note on Monday, August 1st. Finally, Deutsche Bank AG reiterated a “buy” rating and set a GBX 290 ($3.62) price target on shares of Indivior PLC in a research note on Monday, August 1st.

Shares of Indivior PLC (LON:INDV) opened at 338.90 on Monday. The company’s market cap is GBX 2.44 billion. The company’s 50-day moving average price is GBX 329.22 and its 200 day moving average price is GBX 278.38. Indivior PLC has a 52 week low of GBX 126.60 and a 52 week high of GBX 377.00.

TRADEMARK VIOLATION NOTICE: “Brokerages Set Indivior PLC (INDV) Target Price at $369.29” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was stolen and republished in violation of United States & international copyright legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2016/11/24/brokerages-set-indivior-plc-indv-target-price-at-369-29.html.

About Indivior PLC

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of prescription drugs that are based on buprenorphine for treatment of opioid dependence segment. The Company’s treatment and pipeline focuses on opioid use disorder, alcohol use disorder, overdose rescue and co-morbidities of addiction/schizophrenia.

Receive News & Stock Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related stocks with our FREE daily email newsletter.